Sputnik V: All you need to know about Russia s COVID-19 vaccine now approved in India republicworld.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from republicworld.com Daily Mail and Mail on Sunday newspapers.
Russian Covid vaccine over 91 per cent effective trial results suggest RUSSIA S Covid vaccine is 91.6 per cent effective against symptomatic coronavirus, interim trial results suggest. No serious adverse events were deemed to be associated with vaccination, and most reported adverse events were mild, including flu-like symptoms, pain at the injection site and weakness or low energy. Interim data from the phase three trial of the Covid-19 vaccine from Russia, Gam-COVID-Vac (Sputnik V), suggests a two-dose regimen of the vaccine offers 91.6 per cent efficacy. The preliminary findings, published in The Lancet, are based on analysis of data from nearly 20,000 participants, three quarters of whom received the vaccine and one quarter received a placebo.
Russia’s vaccine is 91.6% effective against symptomatic coronavirus, interim trial results suggest.
No serious adverse events were deemed to be associated with vaccination, and most reported adverse events were mild, including flu-like symptoms, pain at the injection site and weakness or low energy.
Interim data from the phase three trial of the Covid-19 vaccine from Russia, Gam-COVID-Vac (Sputnik V), suggests a two-dose regimen of the vaccine offers 91.6% efficacy.
The preliminary findings, published in The Lancet, are based on analysis of data from nearly 20,000 participants, three quarters of whom received the vaccine and one quarter received a placebo.
The jab is a two-part vaccine that includes two adenovirus vectors – recombinant human adenovirus type 26 (rAd26-S) and recombinant human adenovirus type 5 (rAd5-S) – which have been modified to express the SARS-CoV-2 spike protein.
Russia s Sputnik V vaccine against COVID-19 has shown 91.6 per cent efficacy in the phase 3 trial without any serious side effects, according to an interim analysis of data published in The Lancet journal on Tuesday. The findings are based on analysis of data from nearly 20,000 participants, three-quarters of whom received the two-dose regimen of the adenovirus-based vaccine, Gam-COVID-Vac, and one quarter received a placebo. Serious adverse events or those requiring hospital admission were rare in both the placebo and vaccine groups and none were considered associated with vaccination, the researchers said. Four deaths were reported in the trial, none of which were considered related to the vaccine, they said, adding most reported adverse events were mild, including flu-like symptoms, pain at injection site and weakness or low energy.